🇺🇸 cefoperazone sodium and sulbactam sodium in United States

134 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Haemoglobin Decreased — 18 reports (13.43%)
  2. Lymphocyte Count Decreased — 16 reports (11.94%)
  3. Pneumonia — 15 reports (11.19%)
  4. Platelet Count Decreased — 13 reports (9.7%)
  5. Pyrexia — 13 reports (9.7%)
  6. Blood Urea Increased — 12 reports (8.96%)
  7. Diarrhoea — 12 reports (8.96%)
  8. Neutrophil Count Increased — 12 reports (8.96%)
  9. Urinary Tract Infection — 12 reports (8.96%)
  10. Anaemia — 11 reports (8.21%)

Source database →

Other Infectious Disease approved in United States

Frequently asked questions

Is cefoperazone sodium and sulbactam sodium approved in United States?

cefoperazone sodium and sulbactam sodium does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for cefoperazone sodium and sulbactam sodium in United States?

Yung Shin Pharm. Ind. Co., Ltd. is the originator. The local marketing authorisation holder may differ — check the official source linked above.